Laboratorios Farmaceuticos Rovi (ROVIN) Price & Analysis
ROVIN Stock Chart & Stats
- Day’s Range
- MXN 1,128.32 - MXN 1,168.82
- 52-Week Range
- MXN 1,128.32 - MXN 1,711.78
- Previous Close
- MXN 1,168.82
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- MXN 66.59B
- Enterprise Value
- MXN 2.95B
- Total Cash (Recent Filing)
- MXN 128.07M
- Total Debt (Recent Filing)
- MXN 107.69M
- Price to Earnings (P/E)
- 17.3
- Beta
- -0.15
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.43%
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
A debt-free balance sheet gives ROVI substantial financial flexibility to fund capacity, product development, or acquisitions without depending on refinancing. The sizable equity base also improves resilience during weaker pharmaceutical demand and supports investment through operating cycles.
High Profitability And Margins
ROVI’s high gross and net margins indicate that its specialty products, commercial portfolio, and manufacturing activities currently generate attractive economics. Sustained profitability can support internal funding, protect competitiveness, and provide a cushion against rising costs or uneven revenue growth.
CDMO Expansion
Rapid CDMO growth strengthens ROVI’s second earnings engine and increases the contribution from third-party manufacturing relationships. Expansion across Madrid and Phoenix can broaden capacity, improve scale, and make growth less dependent on the performance of any single marketed medicine.
Bears Say
Underlying Profitability Decline
The sharp decline in EBITDA and EBIT excluding the one-off gain shows that reported profit growth overstates underlying operating progress. If this weakness persists, it could constrain reinvestment capacity and reduce the earnings benefit from otherwise strong revenue and CDMO momentum.
Heparin Franchise Contraction
Heparin remains a substantial revenue contributor, so continued year-on-year declines create a durable drag on the product portfolio. Recovery in bemiparin does not yet offset broader LMWH weakness, leaving ROVI dependent on CDMO growth and newer products to replace lost franchise momentum.
Rising Operating Costs
Rapid SG&A and personnel-cost growth can absorb more of the gross profit generated by ROVI’s expanding businesses. Unless revenue growth and operating leverage catch up, sustained cost inflation may pressure margins, reduce cash available for strategic investment, and weaken underlying earnings quality.
Laboratorios Farmaceuticos Rovi News
ROVIN FAQ
What was Laboratorios Farmaceuticos Rovi’s price range in the past 12 months?
What is Laboratorios Farmaceuticos Rovi’s market cap?
When is Laboratorios Farmaceuticos Rovi’s upcoming earnings report date?
How were Laboratorios Farmaceuticos Rovi’s earnings last quarter?
Is Laboratorios Farmaceuticos Rovi overvalued?
Does Laboratorios Farmaceuticos Rovi pay dividends?
What is Laboratorios Farmaceuticos Rovi’s EPS estimate?
How many shares outstanding does Laboratorios Farmaceuticos Rovi have?
What happened to Laboratorios Farmaceuticos Rovi’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Laboratorios Farmaceuticos Rovi?
What is the TipRanks Smart Score and how is it calculated?
Laboratorios Farmaceuticos Rovi Stock Smart Score
Company Description
Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospital solutions for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventions, Multihance and Prohance for MRI, and Sonovue for ultrasounds. It also supplies contrast injection systems such as EmpowerCTA+, EmpowerMR, and CT Exprès, along with compatible disposable materials. The company's offerings extend to over-the-counter pharmaceuticals and contract manufacturing services for other firms, producing a range of dosage forms like prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi serves a broad client base, including pharmaceutical wholesalers, medical professionals, nurses, pharmacists, and individual patients. Notably, Rovi has partnered with Moderna, Inc. for the production of an mRNA COVID-19 vaccine candidate. Established in 1946, the company is headquartered in Madrid, Spain, and operates as a subsidiary of Norbel Inversiones, S.L.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Juan Lopez-Belmonte Encina
- Employees
- 2,470
- Website
- www.rovi.es
- Address
- Calle José Isbert, 2, Pozuelo de Alarcón, 28223, ES
Laboratorios Farmaceuticos Rovi (ROVIN) Earnings & Revenues
ROVIN Earnings Call
Earnings Call SentimentNeutral
The call presented a mix of strong operational and financial positives (double‑digit revenue growth, 38% CDMO growth, improved gross margins, strong cash generation, strategic Phoenix acquisition and clinical progress) alongside material caveats: much of the headline profit uplift was driven by a one‑off EUR 62.4 million badwill, underlying EBITDA and EBIT declined year‑on‑year, SG&A and R&D rose sharply, and the heparin franchise still faces year‑on‑year declines despite recent Q2 improvement. Management maintained cautious full‑year guidance and flagged regulatory and contract timing risks. Overall the results show meaningful momentum in CDMO, cash flow and product development, but underlying operational profitability and cost pressures temper the outlook.
View all MX:ROVIN earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 1 | 9 |
| Technical Analysis | 1 | 1 | 5 |
| Moving Averages | 8 | 0 | 4 |